PIK3CA and breast cancer: The IPATHER study is a phase Ib trial designed to evaluate the safety and efficacy of Ipatasertib in combination with trastuzumab and pertuzumab in patients with locally advanced/unresectable or metastatic PIK3CA-mutant HER2+ breast cancer.